Biosimilars

Brain Cancer

Neoadjuvant HER2+

Breast Cancer

CAR T-cell Therapy

COVID-19

Disparities in Cancer Care

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Gastrointestinal Cancer

Prostate Cancer

Urothelial Cancer

Genitourinary Cancers

Global Oncology

Ovarian Cancer

Gynecologic Oncology

Head & Neck Cancers

Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma

Multiple Myeloma

Myeloproliferative Neoplasms

Non-Hodgkin Lymphoma

Hematologic Oncology

Immunotherapy in GU Cancers

Immunotherapy in Lung Cancer

Immunotherapy in Melanoma

Immuno-Oncology

Lung Cancer

Melanoma & Skin Cancer

Oncology Business Management

Oncology Nursing News

Pediatric Oncology

Special Reports in Personalized Cancer Care

Precision Medicine in Oncology®

Sarcomas/TGCT

Supportive Care

No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

Angela Jia, MD, PhD, discusses the current standing of metastasis-directed radiotherapy in prostate cancer and identifies some lingering questions surrounding the modality.

Dr Jia on the Evolving Role of Metastasis-Directed Radiotherapy in Prostate Cancer

Robert Wang, MD, discusses the presently limited utility of using molecular imagining with quantitative thresholds in distinguishing RCC from oncocytic renal masses.

Dr Wang on the Limited Utility of Quantitative Molecular Imaging Thresholds in RCC

Darolutamide uptake in metastatic hormone-sensitive prostate cancer has become routine both in doublet and triplet regimens in community urology practices.

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

News

OncClub

All Oncology News

Pipeline Report

Media

Insights

MedNews Week

Medical World News

OncChats

OncLive News Network®

OncLive TV

Peer Exchange

Podcasts

Rapid Readouts

The Talk

Conferences

Conference Coverage

Conference Listing

Events

Giants of Cancer Care

PER Events

Scientific Interchanges

State of the Science Summit / IPC

Webinars

Partners

Publications

Oncology Live®

Oncology Fellows

Supplements and Featured Publications

All Publications

CME/CE

Resources

Interactive Tools

Learning Modules

Presentations

Biomarker Consortium

Subscribe

Articles

Nivolumab plus concurrent chemoradiotherapy, followed by nivolumab plus ipilimumab, did not improve PFS in unresectable stage III NSCLC.

Nivolumab/Chemoradiotherapy Regimen Misses PFS End Point in Unresectable, Locally Advanced NSCLC

A retrospective analysis showed that metastasectomy plus radical nephrectomy could improve survival in patients with metastatic non–clear cell RCC.

Retrospective Data Show Metastasectomy Plus Nephrectomy Improves Survival in Non–ccRCC

Joaquim Bellmunt, MD, PhD, discusses the impact of enfortumab vedotin plus pembrolizumab on the treatment paradigm in first-line urothelial cancer. 

EV-302 Trial Ushers in Era of Novel Combos in First-Line Metastatic Urothelial Cancer 

NICE recommends Oncotype DX to guide chemotherapy decisions in early-stage, HR-positive, HER2-negative breast cancer involving up to 3 positive nodes.

NICE Recommends Oncotype DX for Guiding Chemotherapy Decisions in Early-Stage, HR+/HER2– Breast Cancer

OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.

Advertise

About OncLive

Editorial Board

CancerNetwork.com

CGTlive.com

CureToday.com

OncNursingNews.com

TargetedOnc.com

Contact Us

Privacy

Terms & Conditions

Do Not Sell My Information

OncLive - Clinical Oncology News, Cancer Expert Insights

Facebook

Twitter

LinkedIn

Youtube

Spotlight

In-person and virtual events just for HCPs

Specialty

1rem

primary

View

Evolving Treatment Strategies in High-Risk Neuroblastoma

Videos

Giselle Sholler, MD, and Anurag Agrawal, MD, discuss the changing landscape of treatment strategies for patients with high-risk neuroblastoma and review key clinical trial data presented at the ASCO 2023 Annual Meeting.

Giselle Sholler, MD, provides an overview of neuroblastoma, highlighting that 50% of all diagnosed cases in the US are considered high-risk, with a relapse rate of over 40%.

An Overview of Neuroblastoma

Anurag Agrawal, MD, explains his approaches to diagnosing neuroblastoma, including urine markers, imaging, and bone marrow sampling, and emphasizes age and disease dissemination as major prognostic indicators alongside genetic predisposition and treatment response.

Approaches to Diagnosing Neuroblastoma

Dr Giselle Sholler details the role of CURIE scores in measuring bone disease and metastatic spread in neuroblastoma, with a score greater than 12 indicating a worse prognosis.

Role of CURIE Scores in the Treatment and Management of Neuroblastoma

Giselle Sholler, MD, outlines the currently available treatment options for neuroblastoma based on a patient’s risk status.

Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

Anurag Agrawal, MD, discusses how refractory and relapsed neuroblastoma is differentiated, and the typical treatment approaches for both.

Differentiating Refractory and Relapsed Neuroblastoma

Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.

Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.

Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.

Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.

Future Perspectives in the Treatment of Neuroblastoma

Differentiating Refractory and Relapsed Neuroblastoma

EP: 1.An Overview of Neuroblastoma

EP: 2.Approaches to Diagnosing Neuroblastoma

EP: 3.Role of CURIE Scores in the Treatment and Management of Neuroblastoma

EP: 4.Current Treatment Paradigm for Newly Diagnosed Neuroblastoma

EP: 5.Differentiating Refractory and Relapsed Neuroblastoma

EP: 6.Updated Data From the LEAHRN Study in High-Risk Neuroblastoma

EP: 7.Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)

EP: 8.Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials

EP: 9.Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

EP: 10.Future Perspectives in the Treatment of Neuroblastoma

Latest Conference Coverage